Ethan Rowin to Follow-Up Studies
This is a "connection" page, showing publications Ethan Rowin has written about Follow-Up Studies.
Connection Strength
1.081
-
Fath AR, Aglan A, Maron MS, Phillips JS, Maron BJ, Rowin EJ. Cardiovascular outcomes of glucagon-like peptide-1 agonist in patients with obesity and hypertrophic cardiomyopathy. Int J Cardiol. 2025 May 01; 426:133082.
Score: 0.162
-
Aglan A, Fath AR, Maron BJ, Maron MS, Prasad A, Almomani A, Hammadah M, Reynolds MR, Rowin EJ. Percutaneous left atrial appendage closure for stroke prevention in hypertrophic cardiomyopathy patients with atrial fibrillation. Heart Rhythm. 2024 09; 21(9):1677-1683.
Score: 0.154
-
Maron MS, Rastegar H, Dolan N, Carpino P, Koethe B, Maron BJ, Rowin EJ. Outcomes Over Follow-up =10 Years After Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy. Am J Cardiol. 2022 01 15; 163:91-97.
Score: 0.129
-
Carrick RT, Maron MS, Adler A, Wessler B, Hoss S, Chan RH, Sridharan A, Huang D, Cooper C, Drummond J, Rakowski H, Maron BJ, Rowin EJ. Development and Validation of a Clinical Predictive Model for Identifying Hypertrophic Cardiomyopathy Patients at Risk for Atrial Fibrillation: The HCM-AF Score. Circ Arrhythm Electrophysiol. 2021 06; 14(6):e009796.
Score: 0.125
-
Rowin EJ, Maron MS, Chan RH, Hausvater A, Wang W, Rastegar H, Maron BJ. Interaction of Adverse Disease Related Pathways in Hypertrophic Cardiomyopathy. Am J Cardiol. 2017 Dec 15; 120(12):2256-2264.
Score: 0.097
-
Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, Rastegar H, Estes NAM, Maron MS, Maron BJ. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation. 2017 Dec 19; 136(25):2420-2436.
Score: 0.097
-
Rowin EJ, Orfanos A, Estes NAM, Wang W, Link MS, Maron MS, Maron BJ. Occurrence and Natural History of Clinically Silent Episodes of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Am J Cardiol. 2017 06 01; 119(11):1862-1865.
Score: 0.093
-
Rowin EJ, Maron BJ, Appelbaum E, Link MS, Gibson CM, Lesser JR, Haas TS, Udelson JE, Manning WJ, Maron MS. Significance of false negative electrocardiograms in preparticipation screening of athletes for hypertrophic cardiomyopathy. Am J Cardiol. 2012 Oct 01; 110(7):1027-32.
Score: 0.068
-
Boll G, Rowin EJ, Maron BJ, Wang W, Rastegar H, Maron MS. Efficacy of Combined Cox-Maze IV and Ventricular Septal Myectomy for Treatment of Atrial Fibrillation in Patients With Obstructive Hypertrophic Cardiomyopathy. Am J Cardiol. 2020 01 01; 125(1):120-126.
Score: 0.028
-
Maurizi N, Michels M, Rowin EJ, Semsarian C, Girolami F, Tomberli B, Cecchi F, Maron MS, Olivotto I, Maron BJ. Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy. Circulation. 2019 02 05; 139(6):830-833.
Score: 0.027
-
Maron MS, Rowin EJ, Olivotto I, Casey SA, Arretini A, Tomberli B, Garberich RF, Link MS, Chan RHM, Lesser JR, Maron BJ. Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2016 Mar 29; 67(12):1399-1409.
Score: 0.022
-
Maron BJ, Rowin EJ, Casey SA, Lesser JR, Garberich RF, McGriff DM, Maron MS. Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. Circulation. 2016 Jan 05; 133(1):62-73.
Score: 0.021
-
Maron BJ, Casey SA, Chan RH, Garberich RF, Rowin EJ, Maron MS. Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy. Am J Cardiol. 2015 Sep 01; 116(5):757-64.
Score: 0.021
-
Chan RH, Maron BJ, Olivotto I, Assenza GE, Haas TS, Lesser JR, Gruner C, Crean AM, Rakowski H, Rowin E, Udelson J, Lombardi M, Tomberli B, Spirito P, Formisano F, Marra MP, Biagini E, Autore C, Manning WJ, Appelbaum E, Roberts WC, Basso C, Maron MS. Significance of Late Gadolinium Enhancement at Right Ventricular Attachment to Ventricular Septum in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2015 Aug 01; 116(3):436-41.
Score: 0.021
-
Maron BJ, Rowin EJ, Casey SA, Haas TS, Chan RH, Udelson JE, Garberich RF, Lesser JR, Appelbaum E, Manning WJ, Maron MS. Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age. Circulation. 2013 Feb 05; 127(5):585-93.
Score: 0.017